Presentation is loading. Please wait.

Presentation is loading. Please wait.

Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.

Published byFranklin Bond Modified over 5 years ago

Similar presentations

Presentation on theme: "Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm."— Presentation transcript:

1 Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). MDR: multidrug-resistant; ICU: intensive care unit; MRSA: methicillin-resistant Staphylococcus aureus. #: low risk for mortality is defined as a ≤15% chance of dying, a mortality rate that has been associated with better outcomes using monotherapy than combination therapy when treating serious infection [18]. Reproduced from [2]. Antoni Torres et al. ERJ Open Res 2018;4: ©2018 by European Respiratory Society

Download ppt "Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm."

Similar presentations

ARE CAP AND HCAP TWO SEPARATE ENTITIES? Francesco Blasi Department Pathophysiology and Transplantation, University of Milan, Italy.

ARE CAP AND HCAP TWO SEPARATE ENTITIES? Francesco Blasi Department Pathophysiology and Transplantation, University of Milan, Italy.
Role of MRSA Swabs for De-escalation of Antibiotics in HCAP

Role of MRSA Swabs for De-escalation of Antibiotics in HCAP
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.

Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
HAP and VAP Guidelines Update

HAP and VAP Guidelines Update
Nosocomial Antibiotic Resistant Organisms

Nosocomial Antibiotic Resistant Organisms
MRSA Learning Objectives:

MRSA Learning Objectives:
Clinical Microbiology and Infection

Clinical Microbiology and Infection
Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.

Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.
Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.
Volume 139, Issue 5, Pages (May 2011)

Volume 139, Issue 5, Pages (May 2011)
ECDC-EMEA Joint Technical Report Part I: Trends and burden of antimicrobial resistance in the European Union Zsuzsanna Jakab, Director European Centre.

ECDC-EMEA Joint Technical Report Part I: Trends and burden of antimicrobial resistance in the European Union Zsuzsanna Jakab, Director European Centre.
Prevention: The Answer for Bacterial Resistance

Prevention: The Answer for Bacterial Resistance
The challenges of multi-drug-resistance in hepatology

The challenges of multi-drug-resistance in hepatology
A) IS6110 restriction fragment length polymorphism (RFLP) and b) spoligotyping patterns of a multidrug-resistant tuberculosis (MDR-TB) cluster. a) IS6110.

A) IS6110 restriction fragment length polymorphism (RFLP) and b) spoligotyping patterns of a multidrug-resistant tuberculosis (MDR-TB) cluster. a) IS6110.
Clinical Microbiology and Infection

Clinical Microbiology and Infection
Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia  F.P. Paling, M. Wolkewitz, L.G.M. Bode, P.M.C.

Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia  F.P. Paling, M. Wolkewitz, L.G.M. Bode, P.M.C.
European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years.

European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years.
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 
European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after.

European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after.
Clinical impact of antibiotic-resistant Gram-positive pathogens

Clinical impact of antibiotic-resistant Gram-positive pathogens

Similar presentations

Ads by Google